Aadi Bioscience (WHWK): Forward P/S Multiple
Aadi Bioscience Inc (WHWK) develops precision nanoparticles to combat rare tumors. The forward P/S ratio illustrates the efficiency of this targeted delivery, where the value 26.20 represents the current metric. Patent protection for mTOR inhibitors and stringent FDA requirements create significant barriers to entry for competitors. Meanwhile, management is focusing on the commercialization of the therapy and expanding the sales force to achieve profitability.
aadibio.com (WHWK) - metric breakdowns and financial figures
- current price and projected stock value:
- stock exchange capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
- financial results and valuation multiples details:
WHWK - Net Income|Projected Future Earnings Aadi Bioscience Inc|WHWK - Business Payback Period|Forward P/E Multiple Aadi Bioscience|WHWK - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK|WHWK - Operating profit before amortization|Net earnings per share (EPS TTM) Aadi Bioscience|WHWK - Net earnings per share for the last 12 months|Quarterly EPS earnings growth aadibio.com|WHWK - Earnings per share growth rate in current year|Expected earnings per share growth for next year Aadi Bioscience Inc
- sales volume and revenue indicators:
Comprehensive company analysis:WHWK (Aadi Bio)
Aadi Bioscience Inc (WHWK) faces a specific risk profile driven by high R&D expenditures and stringent FDA oversight of the nab-sirolimus platform, which is reflected in the dynamics of market expectations. The forward P/S valuation weighs the current balance of supply and demand against projected revenue, where high volatility in the trend line indicates profit potential coupled with the risk of deep drawdowns.
Competitor analysis
Forward P/S Multiple ONC (BeiGene)|Forward P/S Multiple Halozyme Therapeutics, Inc. HALO|RevMed - Forward P/S Multiple|AAPG (Ascentage Pharma Corp) - Market Cap to Projected Revenue|CGON: Forward P/S Multiple|URGN - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BCAX|PSNL: Forward Price to Sales|Forward P/S Multiple ERAS|Price-to-Projected Revenue Ratio DCTH (Delcath Corp)|Forward P/S Multiple YMAB (Y-mAbs Therapeutics)|Market Cap to Expected Sales Ratio aurabiosciences.com (AURA)|CADL - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Accuray Inc|sellaslifesciences.com (SLS) - Price-to-Projected Revenue Ratio|ACTU - Market Cap to Expected Sales Ratio|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TuHURA (HURA)|Forward P/S Multiple TARA|Market Cap to Expected Sales Ratio Fate Therapeutics Inc|Forward P/S Multiple TCRX (TScan Therapeutics, Inc.)|Champions Oncology Inc (CSBR) - Market Cap to Future Revenue Ratio|XBIT - Price-to-Projected Revenue Ratio|CVM (CEL-SCI Corporation) - Market Cap to Projected Revenue|OSTX: Forward P/S Multiple|Forward Price-to-Revenue Multiple radiopharmtheranostics.com|ARTV (Artiva Biotherapeutics Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Adlai Nortye Limited ANL|Forward Price-to-Revenue Multiple VERU (Veru Inc.)|TPST (tempesttx.com) - Forward Price to Sales|Forward P/S Multiple XLO (Xilio Therapeutics)|Market Cap to Expected Sales Ratio Renovaro Biosciences (RENB)|MURA - Price-to-Projected Revenue Ratio|KAPA (Kairos Pharma Ltd) - Market Cap to Projected Revenue|OKUR: Forward P/S Multiple|Forward Price-to-Revenue Multiple CytoMed Therapeutics Limited|Forward Price-to-Revenue Multiple CRIS|Forward Price-to-Revenue Multiple Apollomics Corp (APLM)|Forward P/S Multiple THAR|ADVB (advanbiomed.com) - Forward Price to Sales|Genprex, Inc. - Forward Price-to-Revenue Multiple|CLDI - Forward Price-to-Revenue Multiple|SBFM - Price-to-Projected Revenue Ratio|XBIO - Forward P/S Multiple|SLRX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Kitov Pharma|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward P/S Multiple beigene.com|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|elevationoncology.com - Market Cap to Projected Revenue|Forward P/S Multiple ICAD (iCAD)|IKNA - Forward Price-to-Revenue Multiple|Notable Labs, Ltd. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Viracta Therapeutics|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Inc - Forward Price to Sales|Forward Price-to-Revenue Multiple AAPGV
